Position in ABSI
as of Mar 31, 2026
· filed Apr 30, 2026
Position Value
$170,280
-$27,812 QoQ
Shares Held
56,760
0.0% QoQ
Ownership
0.036%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ABSI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026GRIFFIN ASSET MANAGEMENT, INC. holds $6,807,021 across 6 Biotechnology names. ABSI ranks #3 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SMMT |
Summit Therapeutics Inc.
|
191,872 | $3,637,893 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,175 | $2,757,384 | |
| 3 | ABSI |
Absci Corp
This page
|
56,760 | $170,280 | |
| 4 | REPL |
Replimune Group, Inc.
|
14,400 | $110,160 | |
| 5 | BMEA |
Biomea Fusion, Inc.
|
58,300 | $89,199 | |
| 6 | SANA |
Sana Biotechnology, Inc.
|
14,620 | $42,105 |
All Filings in ABSI
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $170,280 | 56,760 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $198,092 | 56,760 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $172,550 | 56,760 | Shares | Sole | 2025-10-16 | |
| 2025-06-30 | $250,903 | 97,628 | Shares | Sole | 2025-07-25 | |
| 2025-03-31 | $245,046 | 97,628 | Shares | Sole | 2025-04-16 | |
| 2024-12-31 | $167,051 | 63,760 | Shares | Sole | 2025-01-22 | |
| No filing history on record for this holder in this stock. | ||||||